Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases - Top-Institutions - MDSpire

Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases

  • By

  • Weiqiang Chen

  • Jianhua Li

  • Xiaoling Qiang

  • Li Lou

  • Cassie Shu Zhu

  • Meihong Deng

  • Haichao Wang

  • May 8, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    The Feinstein Institutes for Medical Research (Northwell Health)
    The Feinstein Institutes for Medical Research (Northwell Health)

    Manhasset, New York

    Key Differentiators

    • Rheumatology
    • Immunology

  • #2

    Karolinska Institutet & Karolinska University Hospital, CMM Rheumatology Unit
    Karolinska Institutet & Karolinska University Hospital, CMM Rheumatology Unit

    Stockholm, Sweden

    Key Differentiators

    • Rheumatology

  • #3

    National Institutes of Health
    National Institutes of Health

    Bethesda, Maryland

    Key Differentiators

    • Rheumatology
    • Immunology

  • #4

    University Medical Center Utrecht
    University Medical Center Utrecht

    Utrecht, Netherlands

    Key Differentiators

    • Rheumatology

  • #5

    Hôpital Saint-Louis
    Hôpital Saint-Louis

    Paris, France

    Key Differentiators

    • Rheumatology

Original Source(s)

Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases

  • by Weiqiang Chen, Jianhua Li, Xiaoling Qiang, Li Lou, Cassie Shu Zhu, Meihong Deng, Haichao Wang

  • May 8, 2026

Related Content

Leukemia Case Prompts Broader Review

Researchers assess hematologic malignancies temporally associated with mRNA COVID-19 vaccination.

Case Report: Gangrene after one dose of investigational stannic pentetate radiopharmaceutical

In Memoriam: Steven M. Opal, MD